Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TNFRSF12A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFRSF12A ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View TNFRSF12A Products |
| Gene Delivery | TNFRSF12A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View TNFRSF12A Products |
| Benchmark Ab | Anti-TNFRSF12A Recombinant Antibody Sequence derived from Enavatuzumab (PDL192). Ideal positive control for binding and internalization. |
View TNFRSF12A Products |
| Validator | TNFRSF12A siRNA Set Target-specific knockdown verification in target-expressing cancer cell lines. |
View TNFRSF12A Products |
| Related Target A | TNFSF12 (TWEAK) Natural ligand of TNFRSF12A. Crucial for ligand-blocking assays and signaling cascade validation. |
View TNFSF12 Products |
| Related Target B | TNFRSF21 (DR6) Homologous death receptor. Essential for off-target selectivity and specificity screening. |
View TNFRSF21 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Extremely short extracellular domain (ECD ~32 aa) causing folding instability | Rational design of ECD-Fc fusion constructs to preserve native structural epitopes and maximize shelf-life stability. |
| Cross-species ortholog validation (Human vs. Cyno/Mouse) | Sequence-verified Human, Cynomolgus, and Mouse TNFRSF12A recombinant proteins available with >95% purity. |
| Lack of standardized positive controls for assay setup | Clinical-grade Benchmark Antibodies (Enavatuzumab biosimilar) sequence-verified and expression-optimized. |
| High rates of false positives in cell-based screening | Sequence-validated siRNA pools included for target-specific knockdown control. |
Live TNFRSF12A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNFRSF12A therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to Antibody-Drug Conjugates (ADCs) and bispecific constructs. Because TNFRSF12A is highly overexpressed in multiple solid tumors (including glioblastoma, pancreatic, and non-small cell lung cancer) while maintaining low, restricted expression in normal tissues, it represents an exceptional target for payload-delivery systems. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-localized activation and overcoming resistance in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | AbbVie, Seattle Genetics | Solid Tumors (Pancreatic, Glioma) | Internalization Assay (Requires high-purity ECD-Fc and stable cell lines) |
| Bispecific Antibodies | Innovent Biologics, Roche | Oncology & Autoimmune | Heterodimer Validation (Requires cross-reactive antigens and ortholog panels) |
| Blocking Monoclonal Abs | Biogen, Astellas | Cachexia, Lupus Nephritis | Ligand-receptor blocking assay (Requires high-purity TNFSF12 and TNFRSF12A) |
Title: TNFRSF12A (TWEAKR/CD266) Reagents & Drug Discovery Landscape | TarMart Description: Buy high-purity TNFRSF12A (TWEAKR/CD266) recombinant proteins, biosimilar antibodies, and lentiviral vectors. Analyze clinical trends (ADCs & bispecifics) with our live tracker. Keywords: TNFRSF12A protein, TWEAKR recombinant antigen, CD266 antibody, Enavatuzumab biosimilar, TWEAK TNFRSF12A interaction, ADC internalization assay.